IBDEI044 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1627,2)
 ;;=^59548
 ;;^UTILITY(U,$J,358.3,1628,0)
 ;;=272.0^^18^153^28
 ;;^UTILITY(U,$J,358.3,1628,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1628,1,2,0)
 ;;=2^272.0
 ;;^UTILITY(U,$J,358.3,1628,1,5,0)
 ;;=5^HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,1628,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,1629,0)
 ;;=272.4^^18^153^29
 ;;^UTILITY(U,$J,358.3,1629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1629,1,2,0)
 ;;=2^272.4
 ;;^UTILITY(U,$J,358.3,1629,1,5,0)
 ;;=5^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,1629,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,1630,0)
 ;;=276.7^^18^153^30
 ;;^UTILITY(U,$J,358.3,1630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1630,1,2,0)
 ;;=2^276.7
 ;;^UTILITY(U,$J,358.3,1630,1,5,0)
 ;;=5^HYPERPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,1630,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,1631,0)
 ;;=401.9^^18^153^31
 ;;^UTILITY(U,$J,358.3,1631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1631,1,2,0)
 ;;=2^401.9
 ;;^UTILITY(U,$J,358.3,1631,1,5,0)
 ;;=5^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,1631,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,1632,0)
 ;;=401.1^^18^153^32
 ;;^UTILITY(U,$J,358.3,1632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1632,1,2,0)
 ;;=2^401.1
 ;;^UTILITY(U,$J,358.3,1632,1,5,0)
 ;;=5^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,1632,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,1633,0)
 ;;=401.0^^18^153^33
 ;;^UTILITY(U,$J,358.3,1633,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1633,1,2,0)
 ;;=2^401.0
 ;;^UTILITY(U,$J,358.3,1633,1,5,0)
 ;;=5^HYPERTENSION,MALIGNANT
 ;;^UTILITY(U,$J,358.3,1633,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,1634,0)
 ;;=242.90^^18^153^34
 ;;^UTILITY(U,$J,358.3,1634,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1634,1,2,0)
 ;;=2^242.90
 ;;^UTILITY(U,$J,358.3,1634,1,5,0)
 ;;=5^HYPERTHYROIDISM
 ;;^UTILITY(U,$J,358.3,1634,2)
 ;;=^267811
 ;;^UTILITY(U,$J,358.3,1635,0)
 ;;=272.1^^18^153^35
 ;;^UTILITY(U,$J,358.3,1635,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1635,1,2,0)
 ;;=2^272.1
 ;;^UTILITY(U,$J,358.3,1635,1,5,0)
 ;;=5^HYPERTRIGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,1635,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,1636,0)
 ;;=251.2^^18^153^36
 ;;^UTILITY(U,$J,358.3,1636,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1636,1,2,0)
 ;;=2^251.2
 ;;^UTILITY(U,$J,358.3,1636,1,5,0)
 ;;=5^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,1636,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,1637,0)
 ;;=276.1^^18^153^37
 ;;^UTILITY(U,$J,358.3,1637,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1637,1,2,0)
 ;;=2^276.1
 ;;^UTILITY(U,$J,358.3,1637,1,5,0)
 ;;=5^HYPONATREMIA
 ;;^UTILITY(U,$J,358.3,1637,2)
 ;;=^60722
 ;;^UTILITY(U,$J,358.3,1638,0)
 ;;=276.8^^18^153^38
 ;;^UTILITY(U,$J,358.3,1638,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1638,1,2,0)
 ;;=2^276.8
 ;;^UTILITY(U,$J,358.3,1638,1,5,0)
 ;;=5^HYPOPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,1638,2)
 ;;=^60611
 ;;^UTILITY(U,$J,358.3,1639,0)
 ;;=458.9^^18^153^39
 ;;^UTILITY(U,$J,358.3,1639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1639,1,2,0)
 ;;=2^458.9
 ;;^UTILITY(U,$J,358.3,1639,1,5,0)
 ;;=5^HYPOTENSION NOS
 ;;^UTILITY(U,$J,358.3,1639,2)
 ;;=^60729
 ;;^UTILITY(U,$J,358.3,1640,0)
 ;;=244.9^^18^153^40
 ;;^UTILITY(U,$J,358.3,1640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1640,1,2,0)
 ;;=2^244.9
 ;;^UTILITY(U,$J,358.3,1640,1,5,0)
 ;;=5^HYPOTHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,1640,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,1641,0)
 ;;=599.71^^18^153^6
 ;;^UTILITY(U,$J,358.3,1641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1641,1,2,0)
 ;;=2^599.71
 ;;^UTILITY(U,$J,358.3,1641,1,5,0)
 ;;=5^HEMATURIA,GROSS
 ;;^UTILITY(U,$J,358.3,1641,2)
 ;;=^336611
 ;;^UTILITY(U,$J,358.3,1642,0)
 ;;=599.72^^18^153^7
